UK court OKs Herceptin biosimilar

Share this article:

Biosimilar Herceptin is coming to the UK. Bloomberg reports that a London judge declared two of Roche's patents invalid.

Herceptin patents were set to expire in July but Bloomberg notes this lawsuit was over two additional patents that applied to dosing and composition.

Roche has been preparing for a Herceptin biosimilar for some time, including landing regulatory approval for breast cancer treatment Kadcyla.

Dubbed “super Herceptin,” this treatment combines blockbuster Herceptin with a taxane chemotherapy, as well as a third chemical developed by San Francisco-based ImmunoGen and licensed by Genentech that binds the medicines together.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.